(VIANEWS) – Stellus Capital Investment Corporation (SCM), TPG Specialty Lending (TSLX), Inter Parfums (IPAR) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Stellus Capital Investment Corporation (SCM)
46.1% sales growth and 4.95% return on equity
Stellus Capital Investment Corporation is a business development company specializing in investments in private middle-market companies. It invests through first lien, second lien, unitranche, and mezzanine debt financing, often with a corresponding equity investment. The fund prefers to invest in US and Canada. The fund seeks to invest in companies with an EBITDA between $5 million and $50 million.
Earnings Per Share
As for profitability, Stellus Capital Investment Corporation has a trailing twelve months EPS of $0.71.
PE Ratio
Stellus Capital Investment Corporation has a trailing twelve months price to earnings ratio of 19.63. Meaning, the purchaser of the share is investing $19.63 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 4.95%.
2. TPG Specialty Lending (TSLX)
32.9% sales growth and 9.1% return on equity
Sixth Street Specialty Lending, Inc. (NYSE: TSLX) is a business development company. The fund provides senior secured loans (first-lien, second-lien, and unitranche), unsecured loans, mezzanine debt, and investments in corporate bonds and equity securities and structured products, non-control structured equity, and common equity with a focus on co-investments for organic growth, acquisitions, market or product expansion, restructuring initiatives, recapitalizations, and refinancing. The fund invests in business services, software & technology, healthcare, energy, consumer & retail, manufacturing, industrials, royalty related businesses, education, and specialty finance. It seeks to finance and lending to middle market companies principally located in the United States. The fund invests in companies with enterprise value between $50 million and $1 billion or more and EBITDA between $10 million and $250 million. The transaction size is between $15 million and $350 million. The fund invests across the spectrum of the capital structure and can arrange syndicated transactions of up to $500 million and hold sizeable positions within its credits.
Earnings Per Share
As for profitability, TPG Specialty Lending has a trailing twelve months EPS of $1.49.
PE Ratio
TPG Specialty Lending has a trailing twelve months price to earnings ratio of 12.7. Meaning, the purchaser of the share is investing $12.7 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 9.1%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 43.1%, now sitting on 338.38M for the twelve trailing months.
Dividend Yield
As claimed by Morningstar, Inc., the next dividend payment is on Jun 13, 2023, the estimated forward annual dividend rate is 1.87 and the estimated forward annual dividend yield is 9.89%.
Volume
Today’s last reported volume for TPG Specialty Lending is 228265 which is 51.32% below its average volume of 468941.
3. Inter Parfums (IPAR)
21.1% sales growth and 21.85% return on equity
Inter Parfums, Inc., together with its subsidiaries, manufactures, markets, and distributes a range of fragrances and fragrance related products in the United States and internationally. The company operates in two segments, European Based Operations and United States Based Operations. It offers its fragrance and cosmetic products under the Boucheron, Coach, Jimmy Choo, Karl Lagerfeld, Kate Spade New York, Lanvin, Montblanc, Paul Smith, Repetto, Rochas, S.T. Dupont, Van Cleef & Arpels, Abercrombie & Fitch, Anna Sui, bebe, Dunhill, Hollister, French Connection, Graff, GUESS, Lily Aldridge, MCM, Bella Vita, and Oscar de la Renta brand names, as well as under the Intimate and Aziza names. It sells its products to department stores, specialty stores, duty free shops, beauty retailers, and domestic and international wholesalers, and distributors, as well as through e-commerce. The company was formerly known as Jean Philippe Fragrances, Inc. and changed its name to Inter Parfums, Inc. in July 1999. Inter Parfums, Inc. was founded in 1982 and is headquartered in New York, New York.
Earnings Per Share
As for profitability, Inter Parfums has a trailing twelve months EPS of $4.37.
PE Ratio
Inter Parfums has a trailing twelve months price to earnings ratio of 31.19. Meaning, the purchaser of the share is investing $31.19 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 21.85%.
Growth Estimates Quarters
The company’s growth estimates for the current quarter and the next is a negative 5.8% and a negative 3.1%, respectively.
Dividend Yield
According to Morningstar, Inc., the next dividend payment is on Jun 13, 2023, the estimated forward annual dividend rate is 2.5 and the estimated forward annual dividend yield is 1.83%.
4. Arista Networks (ANET)
17.9% sales growth and 31.99% return on equity
Arista Networks, Inc. develops, markets, and sells cloud networking solutions in the Americas, Europe, the Middle East, Africa, and the Asia-Pacific. The company's cloud networking solutions consist of extensible operating systems, a set of network applications, as well as gigabit Ethernet switching and routing platforms. It also provides post contract customer support services, such as technical support, hardware repair and parts replacement beyond standard warranty, bug fix, patch, and upgrade services. The company serves a range of industries comprising internet companies, service providers, financial services organizations, government agencies, media and entertainment companies, telecommunication service providers, and others. It markets and sells its products through distributors, system integrators, value-added resellers, and original equipment manufacturer partners, as well as through its direct sales force. The company was formerly known as Arastra, Inc. and changed its name to Arista Networks, Inc. in October 2008. Arista Networks, Inc. was incorporated in 2004 and is headquartered in Santa Clara, California.
Earnings Per Share
As for profitability, Arista Networks has a trailing twelve months EPS of $4.82.
PE Ratio
Arista Networks has a trailing twelve months price to earnings ratio of 33.3. Meaning, the purchaser of the share is investing $33.3 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 31.99%.
Sales Growth
Arista Networks’s sales growth is 30.9% for the present quarter and 17.9% for the next.
5. Intuitive Surgical (ISRG)
17.2% sales growth and 11.39% return on equity
Intuitive Surgical, Inc. develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System to enable complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung. It also provides a suite of stapling, energy, and core instrumentation for its surgical systems; progressive learning pathways to support the use of its technology; a complement of services to its customers, including support, installation, repair, and maintenance; and integrated digital capabilities providing connected offerings, streamlining performance for hospitals with program-enhancing insights. The company was incorporated in 1995 and is headquartered in Sunnyvale, California.
Earnings Per Share
As for profitability, Intuitive Surgical has a trailing twelve months EPS of $3.75.
PE Ratio
Intuitive Surgical has a trailing twelve months price to earnings ratio of 87.94. Meaning, the purchaser of the share is investing $87.94 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 11.39%.
Volume
Today’s last reported volume for Intuitive Surgical is 1112990 which is 30.53% below its average volume of 1602310.
Yearly Top and Bottom Value
Intuitive Surgical’s stock is valued at $329.76 at 20:22 EST, higher than its 52-week high of $318.92.
Sales Growth
Intuitive Surgical’s sales growth is 14.1% for the ongoing quarter and 17.2% for the next.
Revenue Growth
Year-on-year quarterly revenue growth grew by 14%, now sitting on 6.43B for the twelve trailing months.
6. Exelixis (EXEL)
14% sales growth and 6.34% return on equity
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. In addition, it is developing XL092, an oral tyrosine kinase inhibitor that targets VEGF receptors, MET, AXL, MER, and other kinases implicated in growth and spread of cancer; XB002, an antibody-drug conjugate composed of human mAb against tissue factor (TF) for the treatment of advanced solid tumors; XL102, an orally bioavailable cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced or metastatic solid tumors; and XB002 for the treatment of non-hodgkin's lymphoma. Exelixis, Inc. has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.
Earnings Per Share
As for profitability, Exelixis has a trailing twelve months EPS of $0.47.
PE Ratio
Exelixis has a trailing twelve months price to earnings ratio of 40.62. Meaning, the purchaser of the share is investing $40.62 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 6.34%.
Sales Growth
Exelixis’s sales growth is 6.4% for the ongoing quarter and 14% for the next.
Revenue Growth
Year-on-year quarterly revenue growth grew by 14.8%, now sitting on 1.66B for the twelve trailing months.
Volume
Today’s last reported volume for Exelixis is 3028850 which is 8.95% above its average volume of 2779860.
